Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.37 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.37 |
| ▸ | MAPT | P10636 | 6/20 | 0.34 |
| ▸ | LMNA | P02545 | 4/20 | 0.34 |
| ▸ | NPSR1 | Q6W5P4 | 4/20 | 0.34 |
| ▸ | MEN1 | O00255 | 3/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.34 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.34 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.34 |
| ▸ | DHODH | Q02127 | 3/20 | 0.34 |
| ▸ | GAA | P10253 | 6/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | PLIN1 | O60240 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | PLIN5 | Q00G26 | 1/20 | 0.33 |
| ▸ | ABHD5 | Q8WTS1 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12916941 | 0.88 | MAPT (0.35) | SMN1; SMN2ALDH1A1CYP2D6MAPTLMNA | |
| SCHEMBL964753 | 0.86 | NPSR1 (0.37) | SMN1; SMN2ALDH1A1CYP2D6MAPTLMNA | |
| SCHEMBL964755 | 0.86 | NPSR1 (0.37) | SMN1; SMN2ALDH1A1CYP2D6MAPTLMNA | |
| SCHEMBL12427256 | 0.85 | MAPT (0.33) | SMN1; SMN2ALDH1A1CYP2D6MAPTLMNA | |
| SCHEMBL12916957 | 0.85 | NPSR1 (0.37) | SMN1; SMN2ALDH1A1CYP2D6MAPTLMNA | |
| SCHEMBL12916928 | 0.84 | NPSR1 (0.36) | SMN1; SMN2ALDH1A1CYP2D6MAPTLMNA | |
| SCHEMBL12427255 | 0.84 | NPSR1 (0.36) | SMN1; SMN2ALDH1A1CYP2D6MAPTLMNA | |
| SCHEMBL1345257 | 0.83 | GAA (0.37) | SMN1; SMN2ALDH1A1CYP2D6MAPTLMNA | |
| SCHEMBL1345256 | 0.83 | GAA (0.37) | SMN1; SMN2ALDH1A1CYP2D6MAPTLMNA | |
| SCHEMBL12130969 | 0.83 | GAA (0.37) | SMN1; SMN2ALDH1A1CYP2D6MAPTLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7977349-B2 | Substituted quinolones III | AICURIS GMBH & CO. KG (DE) | 2011-07-12 | — | — | US | disclosed |
| US-7977349-B2 | Substituted quinolones III | AICURIS GMBH & CO. KG (DE) | 2011-07-12 | — | — | US | disclosed |
| US-7867992-B2 | such as 1-Cyclopropyl-N-(2,4-dichlorobenzyl)-6-fluoro-8-methoxy-7-[3-methyl-4-(2-{[(methylamino)carbonyl]amino}-2-oxoethyl)piperazin-1-yl]-4-oxo-1,4-dihydroquinoline-3-carboxamide, used for the treatment and/or prophylaxis of viral diseases or infections, particularly against cytomegaloviruses | AICURIS GMBH & CO. KG (DE) | 2011-01-11 | — | — | US | disclosed |
| US-7867992-B2 | such as 1-Cyclopropyl-N-(2,4-dichlorobenzyl)-6-fluoro-8-methoxy-7-[3-methyl-4-(2-{[(methylamino)carbonyl]amino}-2-oxoethyl)piperazin-1-yl]-4-oxo-1,4-dihydroquinoline-3-carboxamide, used for the treatment and/or prophylaxis of viral diseases or infections, particularly against cytomegaloviruses | AICURIS GMBH & CO. KG (DE) | 2011-01-11 | — | — | US | disclosed |
| US-20090181996-A1 | SUBSTITUTED QUINOLONES III | BAYER HEALTHCARE AG (DE) | 2009-07-16 | — | — | US | disclosed |
| US-20090181996-A1 | SUBSTITUTED QUINOLONES III | BAYER HEALTHCARE AG (DE) | 2009-07-16 | — | — | US | disclosed |
| US-20070293478-A1 | Substituted quinolones | BAYER HEALTHCARE AG (DE) | 2007-12-20 | — | — | US | disclosed |
| US-20070293478-A1 | Substituted quinolones | BAYER HEALTHCARE AG (DE) | 2007-12-20 | — | — | US | disclosed |
| WO-2007090579-A2 | SUBSTITUTED QUINOLONES III | AICURIS GMBH & CO. KG (DE) | 2007-08-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090181996-A1 | SUBSTITUTED QUINOLONES III | IRF3, TPMT, TOP2A | SMN1; SMN2 3686/4885ALDH1A1 3228/4885CYP2D6 155/4885 |
| US-20070293478-A1 | Substituted quinolones | IRF3, TPMT, NQO2 | SMN1; SMN2 3783/4885ALDH1A1 2853/4885CYP2D6 78/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.